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Abstract
Human kallikrein 8 (hK8), whose gene was originally
cloned as the human ortholog of a mouse brain protease,
is known to be associated with diseases such as ovarian
cancer and Alzheimer’s disease. Recombinant human
pro-kallikrein 8 was activated with lysyl endopeptidase-
conjugated beads. Amino-terminal sequencing of the
activated enzyme demonstrated the cleavage of a 9-aa
propeptide from the pro-enzyme. The substrate specific-
ity of activated hK8 was characterized using synthetic
fluorescent substrates. hK8 showed trypsin-like specific-
ity, as predicted from sequence analysis and enzymatic
characterization of the mouse ortholog. All synthetic sub-
strates tested containing either arginine or lysine at P1
position were cleaved by hK8. The highest kcat/Km value
of 20=103 M-1 s-1 was observed with Boc-Val-Pro-Arg-7-
amido-4-methylcoumarin. The activity of hK8 was inhib-
ited by antipain, chymostatin, and leupeptin. The
concentration for 50% inhibition by the best inhibitor,
antipain, was 0.46 mM. The effect of different metal ions
on the enzyme activity was analyzed. Whereas Naq had
no effect on hK8 activity, Ni2q and Zn2q decreased the
activity and Ca2q, Mg2q, and Kq had a stimulatory effect.
Ca2q was the best activator, with an optimal concentra-
tion of approximately 10 mM.
Keywords: cancer biomarkers; human kallikrein 8;
human kallikreins; kcat/Km; lysyl endopeptidase; serine
protease.
Introduction
In 1995 a protease was cloned from mouse hippocam-
pus cDNA and named neuropsin owing to its expression
Regarding a recommendation for future nomenclature of kallik-
rein gene-derived proteases, see the article ‘A comprehensive
nomenclature for serine proteases with homology to tissue kal-
likreins’ by Lundwall et al., this issue pp. 637–641.
in neurons and its predicted trypsin-like specificity (Chen
et al., 1995). The expression level of this enzyme de-
pends on electrical stimulation and oxidative stress with-
in the limbic system (Chen et al., 1995; Akita et al., 1997).
In kindling mice, a model for plasticity and epilepsy, the
expression was found to be induced in several areas of
the brain (Okabe et al., 1996) and the progression of the
kindling stage was inhibited by intraventricular injection
of monoclonal antibodies specific to neuropsin (Momota
et al., 1998). Therefore, the enzyme is believed to be
associated with brain function, such as memory forma-
tion. Recombinant neuropsin was previously expressed
in a baculovirus expression system and characterized as
a trypsin-like protease, both enzymatically and structur-
ally (Shimizu et al., 1998; Kishi et al., 1999). The human
and rat orthologs were also cloned (Davies et al., 1998;
Yoshida et al., 1998).
Recently, the human ortholog was identified as a new
member of the human kallikrein gene family and was
named human kallikrein 8 (symbols KLK8 for the gene
and hK8 for the protein) (Diamandis et al., 2000a). hK8 is
predicted to be translated into a 250-aa pre-proenzyme,
which is activated by the removal of an N-terminal pre-
propeptide. The predicted active hK8 is 228 aa long and
contains a putative catalytic triad (His, Asp and Ser) typ-
ical for trypsin-like serine proteases. Trypsin-like activity
was also demonstrated for the mouse ortholog mK8.
Recombinant pro-hK8 was expressed using a baculo-
virus expression system, and then purified and used to
develop specific antibodies (Kishi et al., 2003b). By
applying an enzyme-linked immunosorbent assay (ELI-
SA) using these antibodies, hK8 was found to be
expressed in several tissues and biological fluids, indi-
cating that this protease is expressed physiologically and
might be associated with different biological functions or
diseases.
Most human kallikrein members are suggested to be
linked to various cancers, such as testicular, lung, colon,
cervix, breast, ovarian, and/or prostate cancer, and might
prove useful as biomarkers for diagnosis and prognosis
(Borgono and Diamandis, 2004). In particular, prostate
specific antigen (PSA)/human kallikrein 3 (hK3) is an
established biomarker for prostate cancer diagnosis and
prognosis. hK8 was reported to be a candidate biomar-
ker for breast (Yousef et al., 2004b), cervix (Cane et al.,
2004), colon (Yousef et al., 2004a) and ovarian cancers
(Underwood et al., 1999) at the mRNA level, and ovarian
cancer (Kishi et al., 2003a) at the protein level. Further-
more, it has also been suggested that this enzyme is
also associated with Alzheimer’s disease (Shimizu-Okabe
et al., 2001).
In this study, conditions for the activation of recombi-
nant pro-hK8 are reported and the substrate specificity
of activated hK8 was investigated in detail with synthetic
substrates and inhibitors. This report, along with a recent
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Figure 1 Activation conditions for human kallikrein 8.
Influence of incubation time with Lys-C beads on hK8 activity.
(A) hK8 activity evaluated by cleavage of the synthetic substrate
Boc-Val-Pro-Arg-AMC. RFU, relative fluorescence units. (B) hK8
activity evaluated by covalent complex formation with an a1-
antichymotrypsin variant, ACT(PCI). The bands were detected
with a rabbit polyclonal antibody specific for hK8.
Figure 2 Determination of the fraction of active hK8 after
activation.
Lane 1, free hK8 preparation; lane 2, hK8 complexed with an
a1-antichymotrypsin variant, ACT(PCI). The samples were blot-
ted onto nitrocellulose membranes after SDS-PAGE separation
and detected using rabbit anti-hK8 antibody. For details, see the
text. The ratio of inactive hK8 that did not complex with
ACT(PCI) was evaluated to be less than 5% of total hK8.
publication (Rajapakse et al., 2005), describes the
detailed enzymatic characterization of hK8, confirming its
trypsin-like specificity. This work will facilitate identifica-
tion of potential natural substrates and physiological
functions of hK8.
Results
Inhibition of lysyl endopeptidase (Lys-C) activity in
supernatant by TLCK
To inactivate any leakage of Lys-C activity from hK8 acti-
vation beads into the supernatant, we determined the
minimal concentration of TLCK (1-chloro-3-tosylamido-
7-amino-2-heptanone HCl) necessary to inhibit active
Lys-C. At concentrations up to 1 nM there was no detect-
able effect of TLCK on Lys-C activity in the supernatant.
An inhibitor concentration of 1 mM was sufficient to com-
pletely inhibit all residual Lys-C activity (data not shown).
Optimization of hK8 activation with Lys-C-
conjugated beads
To determine optimal activating conditions for hK8, pro-
hK8 was incubated with Lys-C conjugated beads for
varying periods of time. The highest enzyme activity of
activated hK8, measured with Boc-Val-Pro-Arg-AMC,
was observed after 30 min of incubation, with a slight
decrease after 60 min of incubation (Figure 1A). The hK8
activity at each time point was confirmed by analysis of
the complex formation between hK8 and a serpin-type
inhibitor that binds covalently to active hK8. The forma-
tion of complexes between hK8 and the a1-antichymo-
trypsin variant containing a protein C inhibitor-derived
modification of the reactive site loop sequence P3-P29
wACT(PCI)x was observed after 15-min incubation with
Lys-C (Figure 1B). After 60 min of incubation, an addi-
tional protein band at approximately 24 kDa appeared,
which likely represents a degradation product of hK8.
Activation of recombinant hK8
To determine the fraction of active hK8 within the enzyme
preparation, complex formation experiments with the
hK8 inhibitor ACT(PCI) were performed. Recombinant
ACT(PCI), an a1-antichymotrypsin variant containing a
reactive site loop modification derived from protein C
inhibitor, has been described as an inhibitor of hK2 (Clou-
tier et al., 2004). Besides its inhibitory activity on hK2,
ACT(PCI) also inhibits other human tissue kallikreins,
including hK8, by forming stable complexes (unpublished
data). ACT(PCI) was used to quantify active hK8. The
fraction of active hK8 complexed with ACT(PCI) was esti-
mated to be approximately 95% (Figure 2). A very faint
protein band at approximately 24 kDa most likely repre-
sents degraded hK8.
N-Terminal sequencing of the pro-form and active
hK8
Activation of hK8 was assessed by determination of its
N-terminal sequences. The N-terminus of pro-hK8 was
identified as Gly-His-Ser-Arg-Ala-Gln-Glu-Asp-Lys-Val-
Leu, while that of activated hK8 was Val-Leu-Gly-Gly-
His-Glu. These amino acid sequences correspond to
those predicted for hK8 (aa 24–38, SwissProt accession
no. O60259) (Figure 3). The Lys-C cleavage site was
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Table 1 Substrate specificity of hK8.
Substrate kcat/Km (M-1 s-1)a
Z-Phe-Arg-AMC 1.0=103
Z-Gly-Gly-Arg-AMC 1.0=103
Suc-Ala-Ala-Pro-Phe-AMC 0
Boc-Val-Pro-Arg-AMC 2.1=104
MeSuc-Ala-Ala-Pro-Val-AMC 0
Tos-Gly-Pro-Lys-AMC 6.7=102
akcat/Km ratios were analyzed with t3-1(0.1).
Figure 4 pH dependence of human kallikrein 8 activity.
hK8 activity was evaluated by cleavage of the synthetic sub-
strate Boc-Val-Pro-Arg-AMC. At the pH optimum of 8.5, the
activity was defined as 100%. A series of buffers was prepared
to contain 25 mM CH3COOH, 25 mM MES, 75 mM Tris, 25 mM
glycine, 150 mM NaCl and 0.05% Triton X-100.
Figure 3 Activation model for human kallikrein 8.
The sequences are derived from the SwissProt protein database
(accession no. O60259).
Figure 5 Effect of metal ions.
Relative activity was compared by kcat/Km measurements. The
hK8 activity detected for 10 mM Boc-Val-Pro-Arg-AMC substrate
solution in 50 mM Tris-HCl buffer, pH 8.5 at 378C containing
0.05% Triton X-100 was defined as 100% activity. (A) Activation
of hK8 by metal ions. Naq showed no detectable effect. (B) Inhi-
bition of hK8 by metal ions.
found to be identical to the activation site predicted by
gene analysis (Yoshida et al., 1998).
Determination of pH optimum for activated hK8
The influence of pH on hK8 activity was examined within
the range pH 5–10 (Figure 4). There was no detectable
activity below pH 5.5. The pH optimum was approxi-
mately 8.5. The activity dropped to approximately 50%
of that at the pH optimum at pH 7.4 and 10.0.
Enzyme analysis and substrate specificity
The substrate specificity of hK8 was studied using six
synthetic substrates. The catalytic activity values for hK8
using the substrates analyzed are summarized in Table
1. The highest kcat/Km value of 2.1"0.3=104 M-1 s-1 was
found for the substrate Boc-Val-Pro-Arg-AMC (residue
numbers of the substrates are defined as follows: Pn «
P3-P2-P1-P19-P29-P39 « Pn9, with cleavage occurring at
the P1-P19 bond). Lower activity was found with Z-Phe-
Arg-AMC, Z-Gly-Gly-Arg-AMC and Tos-Gly-Pro-Lys-
AMC. Substrates lacking basic amino acids in the P1
position, such as Suc-Ala-Ala-Pro-Phe-AMC and Me-
Suc-Ala-Ala-Pro-Val-AMC, were not cleaved by hK8.
Effects of metal ions
To evaluate the potential effect of metal ions on hK8
activity, Boc-Val-Pro-Arg-AMC cleavage was measured
in the presence of varying concentrations of CaCl2, KCl,
MgCl2, MgSO4, NaCl, NiSO4 and ZnSO4. The effects of
metal ions on hK8 activity are summarized in Figure 5.
CaCl2, KCl and MgCl2 had a positive effect on hK8
activity, with substrate cleavage efficiency increased by
four-, three- and 1.7-fold, respectively. NaCl had no
detectable effect up to a concentration of 1 M. NiSO4 and
ZnSO4 caused a decrease in activity, with concentrations
causing 50% inhibition (IC50) of 11 and 3.3 mM, respect-
ively (Figure 5B).
Effect of protease inhibitors
The effect of several commercial protease inhibitors on
hK8 activity was tested (Figure 6). Whereas the two inhib-
itors against trypsin-like proteases, antipain and leupep-
tin, decreased hK8 activity in a dose-dependent manner,
TLCK, another inhibitor of the same type, did not show
any effect. Inhibition was also observed with chymosta-
tin, a chymotrypsin-like protease inhibitor. Other inhibi-
tors against metalloproteases (EDTA and phospho-
ramidon) and cysteine proteases (E-64) did not affect
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Figure 6 Inhibitor profiling of human kallikrein 8.
Relative activities were compared by kcat/Km measurements. The hK8 activity detected for 10 mM Boc-Val-Pro-Arg-AMC substrate
solution in 50 mM Tris-HCl buffer, pH 8.5 at 378C containing 0.05% Triton X-100 without any inhibitor was defined as 100% activity.
hK8 activity. The IC50 values for antipain, chymostatin
and leupeptin were 0.46, 8.0, and 66 mM, respectively.
Discussion
All human kallikreins have predicted pre-pro-peptides
and are believed to be extracellular proteases. Most kal-
likreins, including hK8, have been detected in biological
fluids as active enzymes or pro-enzymes (Stamey et al.,
1987; Deperthes et al., 1995; Diamandis et al., 2000b,
2002; Luo et al., 2001; Borgono et al., 2003; Kapadia et
al., 2003; Kishi et al., 2003b, 2004; Yousef et al., 2003;
Obiezu et al., 2005). Recombinant hK8 was produced
using a baculovirus expression system and was secreted
into the culture medium as a pro-protein (Kishi et al.,
2003b). One advantage of the baculovirus expression
system is that, generally, post-translational modifications
(removal of signal peptide, glycosylation, etc.) are carried
out as for native proteins when a mammalian gene is
expressed (Maeda, 1989). Sequence analysis predicted
that hK8 has a pro-peptide of four amino acids
(Glu29–Lys32; Yousef and Diamandis, 2001), but N-ter-
minal sequencing of the recombinant hK8 expressed by
the baculovirus system revealed the presence of an addi-
tional five amino acid residues. This 9-aa sequence may
therefore constitute the native pro-peptide for hK8.
Optimal conditions for pro-hK8 activation with Lys-C
beads were observed with a 45-min incubation at 378C.
Further increase in the incubation time led to a decrease
in activity (Figure 1A). This decrease may be due to inac-
tivating cleavage of active hK8 by Lys-C. Active hK8 con-
tains a total of 15 Lys residues, three of which are
positioned close to the active site of the enzyme (Yoshida
et al., 1998). In the mouse ortholog, these Lys residues
are predicted to be on a loop region (Kishi et al., 1999).
Cleavage within this region would give rise to a C-ter-
minal fragment of approximately 25 kDa, corresponding
in size to the band detected by anti-hK8 antibody after
prolonged incubation of hK8 with Lys-C (Figure 1B).
The amount of active hK8 was evaluated in band shift
experiments evaluating complex formation of the prote-
ase with ACT(PCI) (Figures 1B and 2). Shifted bands cor-
responding in size to hK8-ACT(PCI) complexes were
detected. Additional shifted bands, likely to be degra-
dation products of the hK8-ACT(PCI) complex, were
detected after prolonged incubation of hK8 with Lys-C.
It has been shown that the formation of serpin-pro-
tease complexes induces dramatic structural changes
(Huntington et al., 2000), which may facilitate complex
degradation by free proteases.
Like pro-hK8, the proenzymes of hK6, 7, 12, 13, 14
and 15 all have a Lys residue in their respective predicted
activation-site P1 position (Yousef and Diamandis, 2001),
suggesting the potential use of Lys-C in the activation of
these zymogens. Indeed, recombinant hK7 and the
mouse ortholog of hK8 (mK8) were previously shown to
be activated by Lys-C (Hansson et al., 1994; Shimizu
et al., 1998). Furthermore, crystallographic studies of the
kallikreins hK1, hK6 and mK8 revealed very similar struc-
tures (Kishi et al., 1999; Bernett et al., 2002; Gomis-Ruth
et al., 2002; Laxmikanthan et al., 2005). From sequence
analysis of other kallikreins, it is believed that all of them
share a very close ternary structure. This indicates that
Lys-C might be able to access their activation sites and
could prove useful in the activation of their inactive pro-
enzymes, although the activation conditions should be
evaluated in detail to avoid undesirable digestions.
Whereas 1 mM TLCK inhibited Lys-C activity in the
supernatant, TLCK had no detectable inhibitory effect on
hK8 up to 100 mM (Figure 6). These data show that the
enzyme activity detected upon incubation of pro-hK8
with Lys-C beads and treatment with TLCK originates
from activated hK8 and not from contaminating Lys-C
released from the beads.
hK8 cleaves synthetic substrates containing either Arg
or Lys residues at their P1 position (Table 1). This activity
corresponds to a trypsin-like specificity, but the specific-
ity pattern is different compared to other trypsin-like
proteases, including trypsin, thrombin, plasma kallikrein,
urokinase and hK2 (Kishi et al., unpublished data).
Recently, enzyme analysis of recombinant hK8 using
synthetic substrates was reported (Rajapakse et al.,
2005). The substrate specificities observed were very
similar to those found in this study. Minor differences
could be due to the different hK8 production protocol,
since Rajapakse et al. expressed the protease in E. coli
and used a subsequent refolding protocol to obtain
active hK8. mK8 was reported to show an up to five-fold
preference for P1 Arg over Lys (Shimizu et al., 1998).
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Boc-Val-Pro-Arg-AMC and Tos-Gly-Pro-Lys-AMC share
Pro at P2. Although the main difference between these
substrates is the P1 amino acid, there is a more than 30-
fold difference between their kcat/Km ratios for hK8. This
difference is in agreement with the notion that hK8 pre-
fers Arg at P1 position over Lys, and this preference
might be stronger than that of mK8. Whereas the expres-
sion of mK8 in mouse brain was detected at the protein
level (Shimizu et al., 1998), hK8 was not found to be
expressed in appreciable amounts in brain tissue (Kishi
et al., 2003b). These characteristic differences between
hK8 and mK8 may indicate a difference in their physio-
logical functions.
Primary substrate specificity analysis has been report-
ed for the new members of the human tissue kallikrein
family, hK4, 5, 6, 7, 11, 13, and 14 (Egelrud, 1993;
Takayama et al., 2001; Magklara et al., 2003; Kapadia
et al., 2004; Felber et al., 2005; Michael et al., 2005; Luo
et al., 2006). All of them demonstrated trypsin-like activ-
ity, with the exception of the chymotrypsin-like protease
hK7. A comparison of their substrate specificities is com-
plicated by the use of very diverse buffer and substrate
conditions. Nevertheless, Boc-Val-Pro-Arg-AMC was a
favored substrate for these kallikreins. This substrate
might therefore be a promising candidate to test the
enzyme activity of uncharacterized trypsin-like kallikreins,
such as hK10, 12 and 15. hK4, 5, 6, 7, 11, 13, and 14
all clearly favored a P1 Arg over a P1 Lys residue, and
weak selectivity for Lys was only reported for hK4, 8, 13
and 14. Nevertheless, these weak P1 Lys specificities
could be physiologically important, since these proteases
are suggested to be part of an activation cascade involv-
ing various kallikreins (Yousef and Diamandis, 2002) and
7 out of 12 new human kallikreins have P1 Lys at the
predicted activation site.
The influence of metal ions on hK8 activity was tested
using six metal salts. Naq had no detectable effect on
hK8 activity at up to 1 M. The Kq concentration in serum
(3.4–5.0 mM; Basu et al., 2004) is much lower than the
concentration required for hK8 activation (Figure 5A).
Therefore, these metal ions are not expected to influence
hK8 activity under physiological conditions. Serum con-
centrations of Ca2q (2.1–2.5 mM) and Mg2q (0.7–1.0 mM),
on the other hand, are higher than the concentrations
required for increased hK8 activity and might be impor-
tant in regulating hK8 activity under physiological condi-
tions.
Trypsin is known to have a Ca2q-binding site (Bode and
Schwager, 1975). Ca2q binding stabilizes the trypsin
structure and enhances its enzyme activity (Russin et al.,
1974). Ca2q binding also stimulates the activities of chy-
motrypsin and subtilisin. As described for these pro-
teases, increased hK8 activity may be caused by
stabilization of the enzyme structure induced by Ca2q
binding. Amino-acid sequence alignment of trypsin, mK8
and hK8, and structural comparison of trypsin and mK8
(Yoshida et al., 1998; Kishi et al., 1999) showed no inser-
tions or deletions within the Ca2q-binding loop region
among these enzymes. Using structural analysis of tryp-
sin complexed with Ca2q (Bode and Schwager, 1975), it
was shown that this ion associates with five amino acids
on a loop of trypsin with five coordinate bonds. Two out
of these five amino acids, Asn72 and Val75 of trypsin,
associate with Ca2q via their carbonyl oxygens. These
residues are replaced by Ser72 and Asn75 in hK8, which
would not present any particular obstacle for Ca2q bind-
ing. The third amino acid involved in binding, Gln80 of
trypsin, is replaced by Glu80 in hK8; these residues share
the same carbonyl and could form the same coordinate
bond. For the replacement of Gln70 and Glu77 in tryp-
sin by Asp70 and Asp77 in hK8, both of the distances
between these residues and Ca2q would be 1–1.5 A˚
shorter than the original distances to Ca2q for trypsin.
However, these distance differences might be made up
by the interaction between Asp and internal water mol-
ecules (Bode and Schwager, 1975). Therefore, hK8 may
possess a similar Ca2q-binding mechanism as described
for trypsin.
Increased hK8 concentrations were found in serum
from 60% of ovarian cancer patients compared to con-
trols, which indicates that hK8 may be a candidate serum
biomarker for this cancer (Kishi et al., 2003a). One type
of ovarian cancer, hypercalcemic-type small cell carci-
noma of the ovary, shows higher Ca2q serum concentra-
tions (Walt et al., 2001). In these ovarian cancer patients,
hK8 activity could be increased and might be associated
with carcinoma development and metastasis, as reported
for other proteases.
It has been reported that Zn2q inhibits hK2 (Lovgren
et al., 1999), hK3 (Watt et al., 1986), hK5 (Brattsand et
al., 2005), hK7 (Franzke et al., 1996), and hK14 (Bratt-
sand et al., 2005). The predicted Zn2q-binding sites of
hK2 and hK3 are composed of three His residues (Villou-
treix et al., 1994; Lovgren et al., 1999), but sequence
analysis shows that hK8 has only one His residue close
to these corresponding positions (Yousef and Diamandis,
2001). hK5, 7 and 14 also possess only one His residue.
The mechanism by which Zn2q inhibits hK5, 7, 8, and 14
would therefore be expected to be different from that
proposed for hK2 and 3.
A similar inhibitor profile for hK8 was found by Raja-
pakse et al. (2005). Among the protease inhibitors tested
in the current study, antipain, leupeptin and TLCK are
known as trypsin-like protease inhibitors containing Arg
or Lys in the P1 position. The order of these inhibitors for
activity against trypsin has generally been reported as
leupeptin)antipain)TLCK (Jeohn et al., 1995; Valaitis,
1995; Ahsan and Watabe, 2001; Yousef and Diamandis,
2001). Although hK8 has trypsin-like specificity, TLCK
does not inhibit this enzyme up to a concentration of
100 mM and antipain was a better inhibitor of hK8 than
leupeptin (Figure 6). The inhibition profile is therefore
quite different from that observed for trypsin. An unex-
pected result for these inhibitor assays is that chymo-
statin inhibition of hK8 activity is eight-fold greater than
for leupeptin (Figure 6). Chymostatin is an inhibitor of
chymotrypsin-like proteases (Umezawa, 1976). Weak
effects against trypsin-like activity have been reported
for chymostatin, but these effects were always weaker
than those observed for trypsin-like inhibitors (Jeohn et
al., 1995; Valaitis, 1995). Chymostatin was also reported
to have inhibitory activity against mK8, but the inhibitory
activity was lower than for leupeptin (Shimizu et al.,
1998). These data show hK8 inhibitor profile differences
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not only from trypsin, but also from mK8. These differ-
ences in enzyme profiles would support the hypothesis
that hK8 might have different physiological functions than
mK8. Moreover, it cannot be ruled out that hK8 has dual
substrate specificity, as described for hK1 (Fiedler and
Leysath, 1979) and hK14 (Brattsand et al., 2005; Felber
et al., 2005), even if no activity was detectable for hK8
using the chymotrypsin substrate Suc-Ala-Ala-Pro-Phe-
AMC. To answer this question, more detailed specificity
analysis (Cloutier et al., 2002; Felber et al., 2005) or
structural analysis (Laxmikanthan et al., 2005) is
necessary.
In summary, pro-hK8 was activated using Lys-C and
the specificity was found to be trypsin-like. These data
are useful in our efforts to identify natural substrates and
physiological functions for this newly described enzyme.
Materials and methods
Materials
Boc-Val-Pro-Arg-7-amido-4-methylcoumarin (AMC; thrombin
substrate), Tos-Gly-Pro-Lys-AMC (plasmin substrate) and Z-
Phe-Arg-AMC (plasma kallikrein substrate) were from Bachem
(Bubendorf, Switzerland). MeSuc-Ala-Ala-Pro-Val-AMC(elastase
substrate), Suc-Ala-Ala-Pro-Phe-AMC (chymotrypsin substrate),
Z-Gly-Gly-Arg-AMC (urokinase substrate) and tosyl lysyl chlo-
romethyl ketone (TLCK) were from Calbiochem (VWR Interna-
tional AG, Luzern, Switzerland). Lysyl endopeptidase (Lys-C)
was purchased from Wako Pure Chemical Industries, Ltd. (Osa-
ka, Japan). Cyanogen bromide (CNBr)-activated Sepharose 4B
was from Amersham Biosciences (Dubendorf, Germany). Anti-
pain-dihydrochloride, bestatin, chymostatin, L-trans-epoxysuc-
cinyl-leucylamide-(4-guanidino)-butane (E-64) and phospho-
ramidon were from Roche Diagnostics (F. Hoffmann-La Roche
Ltd., Basel, Switzerland). Ethylenediaminetetraacetic acid diso-
dium salt (EDTA-Na2) and leupeptin were purchased from Fluka
(Buchs, Switzerland). Horseradish peroxidase (HRP)-conjugated
goat anti-rabbit IgG was purchased from Jackson Immuno-
Research Inc. (West Grove, PA, USA). Recombinant pro-hK8
(Kishi et al., 2003b) and the a1-antichymotrypsin variant
ACT(PCI) (Cloutier et al., 2004) were prepared as described else-
where. All other reagents used were of analytical grade.
Preparation of Lys-C conjugated beads
Lys-C conjugated beads were prepared according to the
supplier’s instructions. Briefly, one vial of Lys-C (3 U) was con-
jugated to 1 ml of swollen CNBr beads at 48C overnight. The
efficiency of the coupling reaction was monitored by measuring
total protein concentration in the supernatant before and after
the reaction, using absorbance at 280 nm. By measuring the
decrease in protein concentration in the supernatant of the cou-
pling reaction, the binding efficiency was estimated as approx-
imately 45%. Therefore, the quantity of Lys-C on the beads was
estimated to 1.35 U/ml. The activity of Lys-C conjugated on the
beads was confirmed using the Lys-C specific synthetic sub-
strate Tos-Gly-Pro-Lys-AMC (data not shown).
Conditioning of hK8 activation with Lys-C
conjugated beads
A 200-ml aliquot of the purified pro-hK8 (1 mM in 10 mM HEPES
buffer, pH 7.4 containing 500 mM NaCl) was mixed with 2.5 ml
of Lys-C conjugated beads. The mixture was incubated at 378C
on a rotating wheel to activate hK8. Then 30 ml of the incubated
mixture was sampled at 15, 30, 60, and 120 min and centrifuged
at 12 000 g for 1 min. Each supernatant was recovered, snap-
frozen in liquid nitrogen and stored at -808C until enzyme and
titration analysis. After thawing, 2.5 ml of the supernatant sam-
ples was added to 47.5 ml of 200 mM Boc-Val-Pro-Arg-AMC pre-
warmed substrate solution (10 mM HEPES, pH 7.4 and 500 mM
NaCl) on a black 96-well microtiter plate. The fluorescence of
released AMC was monitored (excitation at 340"15 nm, emis-
sion at 485"10 nm) using an FLx800 fluorometric plate reader
(Bio-Tek Instruments, Inc., Winooski, VT, USA). A 10-ml aliquot
of each thawed sample was also mixed with 5 ml of 4 mM
ACT(PCI) solution containing 50 mM Tris-HCl, pH 8.0 (at 378C)
containing 500 mM NaCl and 0.05% Triton X-100 whK8/ACT(PCI)
molar ratio of 1:2x or 5 ml of the same buffer solution lacking
ACT(PCI). The samples were incubated at 378C for 5 h and
then mixed with 5 ml of 4= sodium dodecyl sulfate (SDS) sample
buffer without reducing reagent and incubated at 958C for
10 min. The samples were resolved by 10% SDS-PAGE followed
by Western blot analysis with rabbit anti-hK8 antibody (1/5000
dilution; Kishi et al., 2003b) and HRP-conjugated goat anti-rabbit
IgG (1/10 000 dilution) as the primary and secondary antibodies,
respectively. The HRP activity was detected on X-ray films using
ECL Western blotting detection reagents (Amersham Bio-
science).
Inhibition of Lys-C activity in supernatant by TLCK
The conditions for inhibition of Lys-C activity in supernatants
were evaluated using TLCK, an inhibitor specific for Lys-C. Ali-
quots of 12.5 ml of Lys-C beads were mixed with 1 ml of 10 mM
HEPES buffer, pH 7.4 containing 500 mM NaCl and incubated
at 378C for 45 min. The mixture was centrifuged at 12 000 g for
1 min. Then 90 ml of the supernatant was mixed with 10 ml of
a series of TLCK solutions (final concentration 10-9–10-5 M) and
incubated at room temperature for 40 min. A 90-ml aliquot of
each sample was applied to a 96-well black plate and mixed
with 10 ml of 1 mM Tos-Gly-Pro-Lys-AMC solution. The fluores-
cence signal was monitored as described above.
Activation of recombinant hK8
A 20-ml aliquot of 1 mM pro-hK8 was activated using 250 ml of
Lys-C conjugated beads for 45 min at 378C with rotation. The
supernatant was recovered as previously described. The recov-
ered sample was mixed with TLCK solution (final concentration
1 mM) and incubated at room temperature for 40 min. The mix-
ture was concentrated to 50 mM using Centricon YM-10 (Mil-
lipore, Billerica, CA, USA), frozen in liquid nitrogen and stored at
-808C. The percentage of active hK8 in the sample was evalu-
ated by Western blotting analysis with ACT(PCI) titration whK8/
ACT(PCI) molar ratio of 1:10x. The activities of activated hK8
(act-hK8) samples treated with and without TLCK were also
compared using Boc-Val-Pro-Arg-AMC as substrate.
Amino-terminal sequencing of pro- and active hK8
Samples of 100 pmol of pro- and active hK8 were blotted onto
polyvinylidene fluoride (PVDF) membrane using Prosorb car-
tridges (Perkin Elmer Life and Analytical Sciences, Inc., Boston,
MA, USA). The blotted samples were sequenced by standard
Edman digestion to identify the N-terminal sequences.
Determination of pH optimum for active hK8
The pH optimum for active hK8 was determined using a series
of buffers (pH 5.0–10.0). A four-buffer salt mixture, CH3COOH
(25 mM), 2-(N-morpholino)ethanesulfonic acid (MES; 25 mM), Tris
(75 mM), and glycine (25 mM) were prepared and added to NaCl
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(150 mM) and Triton X-100 (0.05%). The pH was adjusted by
addition of HCl or NaOH. A solution of 10 mM Boc-Val-Pro-Arg-
AMC in each pH buffer (48 ml) was applied to a 96-well black
microtiter plate. The plate was covered to prevent sample evap-
oration and was incubated at 378C for 20 min. Then 2 ml of
2.5 mM hK8 solution was added to each well and the fluores-
cence signal was monitored as described above. kcat/Km values
were calculated as previously described (Elmoujahed et al.,
1990) and plotted against each pH value.
Enzyme analysis of substrate specificity
hK8 activity was tested with six commercial synthetic AMC-con-
taining substrates and their kcat/Km values were calculated as
previously described (Elmoujahed et al., 1990). Each substrate
solution was prepared with 50 mM Tris-HCl, pH 8.5 at 378C con-
taining 150 mM NaCl and 0.1% bovine serum albumin (BSA)
(final substrate concentration 10 mM) and applied to black 96-
well microtiter plates in a total volume of 48 ml. The plates were
covered and incubated at 378C for 20 min. Then 2 ml of 2.5 mM
hK8 solution was added to each well and the fluorescence
was monitored as previously described. These analyses were
performed three times for each substrate-hK8 combination.
Substrate specificities were calculated by direct kcat/Km deter-
mination as previously described (Elmoujahed et al., 1990). All
data were analyzed using Microsoft Excel 2000 (Redmond, WA,
USA). The standard error of the mean for each kcat/Km was nor-
malized by t-distribution with t3-1(0.1) (Campbell, 1989).
Effect of metal ions
The effect of metal ions as inhibitors for hK8 was evaluated
using 10 mM Boc-Val-Pro-Arg-AMC substrate solution in 50 mM
Tris-HCl buffer, pH 8.5 at 378C containing 0.05% Triton X-100.
The concentrations of metal salts tested were: CaCl2, 10-8–1 M;
MgCl2, 10-8–1 M; MgSO4, 10-8–10-2 M; KCl, 10-5–1 M; NaCl, 10-2
–1 M; NiSO4, 10-8–10-4 M; and ZnSO4, 10-9–10-4 M. Solutions of
each metal concentration was applied onto black 96-well micro-
titer plates (volume 48 ml). The plates were covered and incu-
bated at 378C for 20 min. Then 2 ml of 2.5 mM hK8 solution was
added to each well and the fluorescence signal was monitored
as described above. Each condition was tested twice and each
IC50 was evaluated using Microsoft Excel 2000.
Effect of inhibitors
The activities of inhibitors for hK8 were evaluated using 10 mM
Boc-Val-Pro-Arg-AMC substrate solution in 50 mM Tris-HCl buf-
fer, pH 8.5 at 378C containing 0.05% Triton X-100. The concen-
trations of the inhibitors antipain, bestatin, chymostatin, E-64,
leupeptin, phosphoramidon and TLCK tested were 10-9–10-4 M.
Enzyme and statistical analyses were carried out using the same
procedure as described for metal-ion experiments.
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